re: Ann: Phylogica - Isogenica Technology Col...
Now thats where i like to see news travel :-):-)
February 23, 2011 7:18 AM EST
Isogenica and Phylogica Announce Successful Technology Collaboration
strategic alliance fast tracks screening of drug discovery targets
CAMBRIDGE, England--(BUSINESS WIRE)-- Isogenica Ltd (Cambridge, UK) and Phylogica Ltd (ASX: PYC), a leading Australian drug discovery company, have succeeded in a proof of concept project demonstrating compatibility of Isogenicas proprietary CIS in-vitro display technology for peptide engineering and drug discovery with Phylogicas Phylomer drug discovery platform.
Isogenica has been successful in hitting the milestones relating to the collaboration announced in January 2010.
The objectives of the project were to use Isogenicas CIS display to achieve further optimisation of Phylogicas lead compounds targeting CD40 ligand (CD40L).
Phylogica CEO Dr Paul Watt said: This latest milestone has demonstrated Isogenicas CIS display technology is highly compatible with Phylogicas Phylomer libraries. This means the technology can be used to screen trillions of variants of Phylomers in a significantly shorter timeframe than is currently achievable.
Isogenicas technology is well established within the industry and the company has relationships with many of Phylogicas current and prospective pharmaceutical partners.
Dr Watt continued: This combination of the Phylomer libraries with Isogenicas CIS display technology represents a value-adding expansion of Phylogicas drug discovery platform and could open up new partnership opportunities. The two companies are exploring a broader alliance to exploit the unique commercial potential of their combined technologies.
Phylomers are sourced from the most structurally diverse peptide libraries in the world.
The primary screening of Phylomer libraries using CIS display could increase this diversity further, resulting in even higher quality outputs. Moreover, the combined technology offers the ability to screen efficiently against dozens of disease targets in parallel.
Dr Watt added: This increased capacity could also stimulate significant new revenue opportunities for our drug discovery business by expanding our service offering and reducing our cost base.
Isogenicas CEO, Dr Kevin Matthews, said: The pharmaceutical industry is constantly exploring new molecular structures that could lead to significant new medical treatments. The broad structural diversity of Phylogicas Phylomer libraries, combined with the ability to rapidly generate trillions of Phylomer variants, fast-tracks molecular evolution and could generate improved lead candidates in a significantly shorter time frame.
Phylogica scientists are now confident that using the display technology will ensure accelerated screening of the companys vast Phylomer libraries to meet demand from potential pharmaceutical partners.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)